Moscow, Russia, July 25, 2017 – InSysBio LLC (www.insysbio.ru), one of the pioneers in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, announced today a renewal of multi-year Master Service Agreement with ASTEX Pharmaceuticals, Inc.
Within the framework of this cooperation, InSysBio provides priority support for ASTEX research. This gives an opportunity to access the best practices of InSysBio in the field of QSP modeling, as well as significantly reduce the time of initiation and execution of projects.
The renewal of the ASTEX agreement once again shows that QSP is a necessary technology to support discovery and development of new drugs in oncology and immuno-oncology therapeutic areas. Such an approach improves all stages of the development: it helps to make strategic GO/ NO GO decisions for research, prioritize targets and compounds, interpret results from animal studies and select optimal design(s) for clinical trials.
"We are very pleased ASTEX has chosen to renew our multi-year Master Service Agreement. It underscores that our partners are satisfied with our services and would like to extend this fruitful and reliable collaboration," said Founder and CEO Oleg Demin, PhD.
← | February 2022 | → | ||||
Mo | Tu | We | Th | Fr | Sa | Su |
---|---|---|---|---|---|---|
1
|
2
|
3
|
4
|
5
|
6
| |
7
|
8
|
9
|
10
|
11
|
12
|
13
|
14
|
15
|
16
|
17
1.
17 Feb 2022 15:58
InSysBio to present its poster at Tau2022 Global Conference
InSysBio announces its participation in Tau2022 Global Conference. Tau2022 is held virtually on February 22-23, 2022. InSysBio team presents a poster within its frames
|
18
|
19
|
20
|
21
|
22
|
23
|
24
1.
24 Feb 2022 15:27
InSysBio to participate in ASCPT 2022
InSysBio announces its participation in ASCPT 2022 Annual Meeting which is to be held virtually March 16-18, 2022. InSysBio is going to give a talk in frames of its Micro-Theater Session with live Q&A which is scheduled for 3:30 PM ET, Thursday, March 17th. InSysBio team will also present two posters
|
25
|
26
|
27
|
28
|